New York, NY — April 11, 2023 — Oshi Health, the virtual specialty care company transforming gastrointestinal (GI) health outcomes and economics, today announced that it has raised $30 million in Series B funding led by Koch Disruptive Technologies (KDT) and joined by existing investors Bessemer Venture Partners, Flare Capital Partners, Frist Cressey Ventures, CVS Health Ventures and Takeda Digital Ventures. This funding will bolster the company’s market leadership and momentum, as its recent clinical study results are driving accelerated contracting with payers and employers to reimburse access to Oshi Health as a covered benefit. The rigorous clinical trial of Oshi Health’s differentiated clinical model, conducted by a national health plan in…
Author: Rutali Thakur
Key takeaways: A 4-week, in-hospital program of exercise, nutritional intervention and psychological support resulted in fewer postoperative complications. Prehabilitation also improved functional recovery. Multimodal prehabilitation reduced the incidence of severe postoperative complications and enhanced functional recovery among patients who underwent elective resection of non-metastasized colorectal cancer, according to data. read more
Owlstone Medical has announced the launch of OMED Health, a dedicated, patient-centric brand and digital platform that will offer patients and clinicians access to breath-based diagnostic tests, point-of-care devices and support resources for a range of conditions. Initially focused on digestive disease, OMED Health will help individuals with gut health issues have an improved quality of life by enabling better, and faster, understanding and management of their conditions. read more
It takes a minute to find the Austin offices of Noah Kraft and Lucas Kraft, the red-headed brothers behind Wonderbelly, a new antacid heartburn reliever. They’re tucked up on the attic floor of a historic building on the city’s East Side, where startups like this one share real estate with new condos and veteran bars. Colorful rugs and a slew of Mac-topped desks dress up the low-ceilinged rooms, and evidence of late nights—a 12-cup coffee maker, a microwave, and bags of takeout—lurk in the corners. It’s exactly the kind of “before” office that the Kraft brothers might remember with nostalgia if…
BOSTON, April 10, 2023 /PRNewswire/ — Published today, Bain & Company’s 12th annual Global Healthcare Private Equity and M&A report reflects the continued resilience of the healthcare industry, with 2022 seeing near-record levels of healthcare dealmaking, in terms of both volume and value. Despite a slowdown caused by macro-economic and geopolitical forces in the second half of the year, 2022 was still the second-best year on record for healthcare dealmaking, due in large part to the white-hot pace of investment at the start of the year. Total disclosed deal value reached nearly $90 billion, down from $151 billion in 2021…
In 2023, there have already been several updates to guidelines and recommendations in gastroenterology care from ACG and AGA, including managing celiac disease, acute lower GI bleeding, ulcerative colitis and diagnosing biliary strictures. Additionally, the ACG revamped recommendations for management of subepithelial GI lesions and, most recently, published a clinical practice update on management of patients with alpha-gal syndrome, which manifests with common GI symptoms and is caused by Lone Star tick bites. Read more
US regulators may soon clear blood-based biomarker tests for colorectal cancer (CRC), expanding potential options for patients seeking more convenient forms of screening. Most recently, Guardant Health, Inc, announced the completion of its US premarket approval application for its Shield blood test to screen for CRC. Approval by the US Food and Drug Administration (FDA) would position Guardant to later secure Medicare coverage for its test. Rival companies, including CellMax Life, Freenome, and Exact Sciences, which already offers the stool-based Cologuard product, are pursuing similar paths in their development of blood tests for CRC. read more
RENTON, Wash. & MENLO PARK, Calif.–(BUSINESS WIRE)–Providence, a not-for-profit health system serving the Western U.S., and GRAIL, LLC, a healthcare company with a mission to detect cancer early when it can be cured, today announced the expansion of their partnership to offer multi-cancer early detection screening as part of clinical care to eligible individuals across the entire Providence health system. Through the partnership, eligible patients at Providence’s 52 hospitals and 900 clinics across seven states will have access to GRAIL’s Galleri® multi-cancer early detection (MCED) test, as part of a comprehensive range of health services. In clinical studies, Galleri has demonstrated…
ATLANTA, March 30, 2023 /PRNewswire/ — Kohlberg & Company (“Kohlberg”), a leading private equity firm headquartered in New York, today announced that it has partnered with United Digestive (“UD”), one of the largest gastroenterology physician practice management firms in the United States. United Digestive offers a unique, fully integrated management platform for gastroenterology practices and has over 200 providers across 80 locations in the Southeastern United States. UD was formed from a partnership between Atlanta Gastroenterology Associates and Frazier Healthcare Partners in December 2018. read more
Capsulomics, announces official rebrand as Previse and launches their first product to enable accurate prognosis and detection data for those prone to Esophageal Cancer. BALTIMORE, March 21, 2023 /PRNewswire/ — Previse, formerly known as Capsulomics, Inc., announced that the company has closed a $3M seed round and launched its first laboratory-developed test, Esopredict™. Esophageal cancer is one of the most lethal cancers in the world, with a 20% five-year survival rate after diagnosis. According to the American Cancer Society, in 2023, about 21,560 new US cases of esophageal cancer will be diagnosed, and 16,120 people will die from the disease.…